The global ophthalmic drugs market has witnessed significant growth in recent years, driven by an increase in the prevalence of eye disorders and diseases. Valued at US$ 31.4 billion in 2022, the market is projected to grow at a CAGR of 6.2% from 2023 to 2031, reaching over US$ 52.8 billion by 2031. The rising incidence of conditions such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy, especially among the aging population, has significantly increased the demand for effective ophthalmic drugs. Moreover, advancements in drug delivery technologies, increased healthcare expenditure, and growing awareness of eye health are contributing to market expansion. However, regulatory hurdles, the high cost of drug development, and competition from generic alternatives pose challenges to market growth.
Dive into the most impactful insights from our Report in this sample
Key Drivers and Industry Trends
Rise in Prevalence of Eye Disorders and Diseases
The increasing occurrence of eye diseases is a primary driver of market growth. Factors such as aging populations, unhealthy lifestyles, and the rising prevalence of diabetes contribute to the surge in ophthalmic conditions. According to the World Health Organization (WHO), over 2.2 billion people globally suffer from some form of visual impairment, with many cases being preventable or treatable. Additionally, the American Academy of Ophthalmology projects that the number of people affected by age-related macular degeneration (AMD) will rise from 196 million in 2020 to 288 million in 2040. The escalating burden of eye diseases necessitates the development and distribution of effective ophthalmic drugs.
Increase in Awareness about Eye Health
Public awareness about eye health has grown due to campaigns by government organizations, NGOs, and healthcare institutions. Events such as World Sight Day, organized by the International Agency for the Prevention of Blindness (IAPB), emphasize the importance of regular eye check-ups and early disease detection. Initiatives by Orbis International, Sight Savers, and the National Eye Institute further reinforce the need for improved access to ophthalmic drugs and treatments. These awareness efforts have led to increased patient adherence to prescribed ophthalmic treatments, fueling market growth.
Surge in Demand for Anti-VEGF Drugs
Among various therapeutic classes, anti-VEGF (vascular endothelial growth factor) agents dominate the market due to their effectiveness in treating retinal disorders such as diabetic retinopathy and AMD. The introduction of innovative products, such as Valitor’s anti-VEGF antibody conjugate platform in December 2022, is expected to enhance treatment efficacy and patient outcomes. The growing geriatric population, who are at a higher risk of these disorders, is a major factor in the increasing demand for anti-VEGF drugs.
Advancements in Drug Delivery Technologies
Innovations in nanoparticle-based drug delivery, sustained-release formulations, and smart eye drops are revolutionizing ophthalmic treatments. These advancements help improve therapeutic efficacy, reduce dosing frequency, and enhance patient compliance. Companies such as Alcon and Novaliq are at the forefront of developing next-generation eye drop formulations that minimize side effects while ensuring sustained drug release.
Regional Outlook
North America: Market Leader
North America holds a significant share of the ophthalmic drugs market, with the U.S. leading in revenue generation. Factors such as the high prevalence of eye diseases, strong healthcare infrastructure, and presence of key market players contribute to the region’s dominance. According to the CDC, approximately 12 million Americans aged 40 and older suffer from vision impairment, including 1 million cases of blindness. Additionally, companies such as Regeneron Pharmaceuticals, Allergan/AbbVie, and Alcon Vision LLC continue to drive innovation and expand product portfolios, further strengthening the market.
Asia Pacific: Fastest-Growing Region
The Asia Pacific ophthalmic drugs market is anticipated to expand at the fastest CAGR during the forecast period. The region’s high disease burden, expanding healthcare access, and emergence of local pharmaceutical firms contribute to market growth. Countries such as China, India, and Japan are investing heavily in ophthalmic drug research and development. Partnerships, such as Novotech’s collaboration with the Asian Eye Institute, aim to improve clinical research capabilities and accelerate the introduction of new ophthalmic treatments.
Competitive Landscape
The ophthalmic drugs market is highly competitive, with major pharmaceutical companies engaging in strategic mergers, acquisitions, and product launches to strengthen their market position. Key players include:
- AbbVie, Inc.
- Alcon Vision LLC
- Bausch Health Companies, Inc.
- Bayer AG
- Coherus BioSciences
- F. Hoffmann-La Roche Ltd.
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
- Regeneron Pharmaceuticals, Inc.
- Santen, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
Recent Market Developments
- April 2022 – Sandoz (Novartis division) launched a generic combination eyedrop for ocular hypertension in the U.S.
- January 2022 – F. Hoffmann-La Roche Ltd. received FDA approval for Vabysmo, a treatment for wet AMD and diabetic macular edema.
- October 2021 – AbbVie, Inc.’s Vuity eye drops became the first FDA-approved treatment for presbyopia.
- September 2021 – Teva Pharmaceuticals USA, Inc. introduced the first generic version of AZOPT for ocular hypertension and open-angle glaucoma.
Stay informed with the latest insights—read our full report
Market Segmentation
The global ophthalmic drugs market is segmented based on therapeutic class, indication, route of administration, product type, dosage form, and distribution channel:
By Therapeutic Class:
- Anti-VEGF Agents
- Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs)
- Anti-inflammatory Drugs (Steroids, NSAIDs)
- Anti-infective Drugs (Anti-bacterial, Anti-fungal)
- Anti-allergy Drugs
By Indication:
- Dry Eye
- Glaucoma
- Retinal Disorders (Wet AMD, Dry AMD, Diabetic Retinopathy)
- Allergy
- Uveitis
By Dosage Form:
- Eye Drops
- Eye Solutions & Suspensions
- Capsules & Tablets
- Gels & Ointments
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030USA – Canada Toll Free: 866-552-3453
